{"Symbol": "MRNS", "AssetType": "Common Stock", "Name": "Marinus Pharmaceuticals, Inc", "Description": "Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "5 Radnor Corporate Center, Radnor, PA, United States, 19087", "FullTimeEmployees": "42", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "240741888", "EBITDA": "-45371000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.756", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.982", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.4554", "ReturnOnEquityTTM": "-0.8605", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.968", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "5.44", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "2.4069", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "2.0225", "52WeekHigh": "3.41", "52WeekLow": "1.01", "50DayMovingAverage": "1.8675", "200DayMovingAverage": "2.1668", "SharesOutstanding": "122195000", "SharesFloat": "82920090", "SharesShort": "7622845", "SharesShortPriorMonth": "6681812", "ShortRatio": "6.18", "ShortPercentOutstanding": "0.09", "ShortPercentFloat": "0.0935", "PercentInsiders": "0.625", "PercentInstitutions": "70.287", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}